# Hematuria Treatment Market > Hematuria Treatment Market Research Report: Information By Type (Gross Or Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, Jogger's Hematuria), By Causes (Kidney Stones, Urinary Tract Infections (UTI), Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, Menstruation), By Treatment (Drugs, Therapeutics, Others), By End-Users (Hospitals, Clinics, Laboratories, Research Centers, Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 2.7% - **2024:** $ 1.16 Billion - **2025:** $ 1.19 Billion - **2035:** $ 1.56 Billion - **Key Players:** AstraZeneca (GB), Bristol-Myers Squibb (US), Pfizer (US), Novartis (CH), Roche (CH), Johnson & Johnson (US), Merck & Co. (US), Eli Lilly and Company (US), Sanofi (FR) **Report ID:** MRFR/MED/1200-HCR · **Pages:** 85 · **Author:** Satyendra Maurya & Kinjoll Dey · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/hematuria-treatment-market-1732 --- ## Market Summary ## **Global Hematuria Treatment Market Overview** Hematuria Treatment Market Size was valued at USD 1.1 Billion in 2022. The Hematuria Treatment market industry is projected to grow from USD 1.13 Billion in 2023 to USD 1.40 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 2.70% during the forecast period (2023 - 2032). Rising chronic disease incidence is the key market drivers accelerating market expansion. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review In November 2023, EndoChoice Holdings, Inc. announced that it had completed the medical trials that have shown or demonstrated the efficacy of its endoscopic technology for diagnosing and treating hematuria. KARL STORZ SE & Co. KG launched the newest ureteroscope constructed in October 2023 to enhance diagnostics along with interventions within hematuria and additional urogenital diseases.  Richard Wolf GmbH introduced a flexible ureteroscope having or consisting of new imaging capabilities improving the treatment and therapy of hematuria along with other urogenital pathologies in July 2022. The newest cystoscopy system from Boston Scientific Corporation approved by FDA in May 2022, is aimed at increasing the visibility during procedures of hematuria management problems, including other urinary pathway malformations. Farxiga (dapagliflozin) oral tablets were approved by the FDA in April 2021 for lowering kidney failure, cardiovascular mortality, renal function decline and heart stoppage hospitalization abnormalities among people or individuals having chronic kidney disease who are prone to the progression of their chronic renal disorder. Astra Zeneca and Vax Equity announced their collaboration in September 2021 for the RNA therapeutics platform development and commercialization. In February 2020, Exblifep by Da Volterra was launched to satisfy unmet needs for complex UTIs, a combination of enmetazobactam, a new extended-spectrum beta-lactamase inhibitor and cefepime which is dedicated to fourth-generation cephalosporin that had satisfied primary endpoints within this clinical research program. FDA approved Recarbrio (imipenem-cilastatin-relebactam) in 2019 for treating patients with complex urinary tract infections (cUTI) and difficult intra-abdominal infections (cIAI). ## **Hematuria Treatment Market Trends** Market CAGR for hematuria treatment is being driven by the rising chronic disease incidence. Bleeding in the urine is referred to clinically as hemoturia. Humans produce urine, which is filtered by a kidney, which normally keeps blood out of the urine. Blood in the urine is a symptom of many different medical disorders, including kidney damage, cancer, enlarged prostate, bladder stones, kidney infections (pyelonephritis), and renal illness, and kidney disease, Urinary tract infections. Investigating the clinical aetiology of hematuria is crucial because, if addressed, it could develop into a potentially fatal illness. Despite the fact that blood in the urine is not usually an indication of sickness, it can be a serious indicator of a potential medical problem. Different antibiotics are suggested for treatment depending on which part of the tract is being addressed. Additionally, the rising prevalence of chronic diseases has caused a significant increase in healthcare spending, which is a key factor in the market's revenue growth. The modernization of healthcare infrastructure is being funded in large part by the governments of various economies. Additionally, patients in industrialized economies are learning more about the hematuria treatments that are accessible. Oral medications are predicted to accelerate market expansion. Given that the majority of medications are accessible in capsule and tablet form and that this is a very practical mode of administration, the category is anticipated to accelerate the market. The operations and the projected market growth that have been set for the forecast period are likely to be hampered by the arrival of numerous decrease in the availability of medical experts to provide hematuria treatment. The ability for pharmaceutical companies to introduce novel medicines and potential pipeline products has been made possible by intensive research and development efforts, the advent of high-throughput screening (HTS) for drug development, and approval by the FDA for drugs. Furthermore, rising opportunities for related therapies are projected to offer significant potential opportunities for the players in the hematuria treatment market to increase their client bases, particularly in emerging nations. For instance, overactive bladder symptoms are present in 70% to 80% of persons over the age of 80, according to the International Incontinence Society. People over the age of 35 are more likely to experience the symptoms of hematuria, which is more common as people become older. Thus, result in driving the Hematuria Treatment market revenue. ## **Hematuria Treatment Market Segment Insights** ### **Hematuria Treatment Type Insights** The Hematuria Treatment market segmentation, based on type includes Gross or Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger's Hematuria. The microscopic hematuria segment dominated the market in the year 2022. The segment is dominating the market because more people are becoming hematuric with tiny blood in their urine. Microscopic hematuria is typically diagnosed during routine testing rather than after the patient experiences symptoms. ### **Hematuria Treatment Causes Insights** The Hematuria Treatment market segmentation, based on Causes, includes Kidney Stones, [Urinary Tract Infections](../../../reports/urinary-tract-infection-market-6138) (UTI), Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation. The urinary tract infections (UTI) category generated the most income. The key factor boosting the market is the rise in UTI infections among women. The urinary system as a whole is affected by a urinary tract infection, including the kidneys, bladder, urethra, and other areas. ### **Hematuria Treatment Treatment Insights** The Hematuria Treatment market segmentation, based on Treatment, includes Drugs, Therapeutics, and Others. The drugs category generated the most income. Considering the illness, the amount of urine that is expelled from the body is increased by antibiotics and drugs, and the labor that the kidneys must do is lessened by blood pressure medications and dietary changes. ### **Hematuria Treatment End-Users Insights** The Hematuria Treatment market segmentation, based on End-Users, includes Hospitals, Clinics, Laboratories, Research Centers, and Others. The hospitals generated the most income. This is due to the fact that numerous pharmaceutical companies have used cutting-edge techniques and technologies to meet the needs and demands of the general public for the treatment of hematuria. Additionally, the use of antibiotics to treat urinary tract infections, shock wave therapy to treat bladder or kidney stones, and medications to shrink enlarge prostate glands are contributing to the rise of the hospital segment's market during the forecast period. **Figure1: Hematuria Treatment Market, by End-Users, 2022&2032 (USD Billion)**  _Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review_ ### **Hematuria Treatment Regional Insights** By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The Asia Pacific Hematuria Treatment market area will be dominant, due to the expansion of healthcare facilities, the prevalence of generic manufacturers, the growth of government initiatives, and the emergence of specialized communities. Further, the major countries studied in the market report are The US, Germany, Canada, France, the United Kingdom, Italy, Spain, Australia, South Korea, and Brazil. **Figure2: HEMATURIA TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)**  _Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review_ Europe Hematuria Treatment market accounts for the second-largest market share due to the desire for novel therapies, as well as other significant reasons including the enormous research being conducted in the area of treating urinary tract infections, the market participants have begun to expand internationally. Further, the German Hematuria Treatment market held the largest market share, and the UK Hematuria Treatment market was the European region's fastest-growing market. The North America Hematuria Treatment Market is predicted to see the highest CAGR between 2023 and 2032. This is because of the early adoption of branded products, favorable healthcare reimbursement regulations, recent FDA permits, the vast number of drugs in development, the emphasis on reducing the overall number of unresolved hematuria cases, and the early treatment of hematuria. Moreover, China’s Hematuria Treatment market held the largest market share, and the Indian Hematuria Treatment market was the Asia-Pacific region's fastest-growing market. **Hematuria Treatment Key Market Players& Competitive Insights** Leading market players are paying a large sum of money on research and development in order to expand their product lines, which will help the Hematuria Treatment market, grow even more. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other organizations. To grow and endure in an increasingly competitive and challenging market environment, Hematuria Treatment industry must provide affordable options. One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the Hematuria Treatment industry to benefit clients and increase the market sector. In recent years, the Hematuria Treatment industry has offered some of the most significant advantages to medicine. Major players in the Hematuria Treatment market, including AstraZeneca Plc. Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Novartis International AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, The Medicines Company and others are making investments in research and development activities in an effort to boost market demand. AstraZeneca plc is a worldwide pharmaceutical and biotechnology business with British and Swedish roots. Its headquarters are in Cambridge, England's Cambridge Biomedical Campus. Its product portfolio covers cancer, cardiovascular, gastrointestinal, infectious, neurological, respiratory, and inflammatory illnesses. It has been among the largest pharmaceutical corporations in the world since the merger and has acquired a number of businesses, notably Cambridge Antibody Technology. In 2021, India authorized the use of the Oxford-AstraZeneca vaccine, opening the door for a widespread immunization campaign in the second-most populous nation in the world. It was revealed that the Oxford-AstraZeneca shot would be produced domestically by the Serum Institute of India (SII) under the trade name COVISHIELD. The Bristol-Myers Squibb Company (BMS) is a pharmaceutical company with headquarters in the US. With its headquarters in New York City, one of the largest pharmaceutical companies in the world, BMS routinely makes the Fortune 500 list of the largest American companies. Cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders are among the therapeutic areas where Bristol Myers Squibb produces prescription medications and biologics. Lawrence, New Jersey, Summit, New Jersey, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain are the locations of BMS's main research and development facilities. Additional facilities can be found in Devens and Cambridge in Massachusetts, East Syracuse, New York, Braine-l'Alleud, Belgium, and Tokyo in Japan, India's Bangalore, and Wirral, United Kingdom. In the past, BMS operated an R&D facility in Wallingford, Connecticut. In June 2022, BMS announced that it would buy Turning Point Therapeutics Inc. for $4.1 billion in cash ($76 per share, a 122.5% premium to its most recent closing price), expanding its line-up of cancer medications to include repotrectinib. **Key Companies in the Hematuria Treatment market include** **Hematuria Treatment Industry Developments** _**April 2019:**__Otsuka Pharmaceutical Co., Ltd. declared that, JYNARQUE (tolvaptan) has been approved by the FDA as the first medication to be used to stop kidney function decline in persons at risk of autosomal dominant polycystic kidney disease increasing quickly._ _**April 2021:**__FDA-approved oral tablets of Farxiga (dapagliflozin) to lower the risk of renal function loss, kidney failure, cardiovascular death, and heart failure hospitalization in chronic renal disease patients who are at risk of disease progression._ _**June 2021:**__Eisai Co., Ltd. and Bristol-Myers Squibb Company have entered into an exclusive strategic collaboration agreement, in order to jointly develop and market MORAb-202, an antibody drug conjugate (ADC)._ ## **Hematuria Treatment Market Segmentation** ### **Hematuria Treatment Type Outlook** ### **Hematuria Treatment Causes Outlook** ### **Hematuria Treatment Treatment Outlook** ### **Hematuria Treatment End-Users Outlook** ### **Hematuria Treatment Regional Outlook** ## Market Drivers ### Growing Geriatric Population The expanding geriatric population is a significant factor influencing the Hematuria Treatment Market. As individuals age, the likelihood of developing conditions associated with hematuria, such as bladder cancer and kidney stones, increases. According to demographic data, the proportion of individuals aged 65 and older is projected to rise, leading to a higher incidence of hematuria-related health issues. This demographic shift necessitates a corresponding increase in treatment options tailored to the needs of older patients. Consequently, the Hematuria Treatment Market is likely to experience growth as healthcare providers seek to address the unique challenges posed by this aging population. ### Rising Incidence of Hematuria The increasing prevalence of hematuria, often indicative of underlying health issues, is a primary driver of the Hematuria Treatment Market. Studies suggest that hematuria affects approximately 2-3% of the population, with higher rates observed in older adults. This rise in incidence necessitates effective treatment options, thereby propelling market growth. As healthcare providers become more vigilant in diagnosing and treating hematuria, the demand for innovative therapies and diagnostic tools is likely to escalate. Furthermore, the correlation between hematuria and serious conditions such as urinary tract infections and kidney diseases underscores the urgency for timely intervention, which in turn fuels the Hematuria Treatment Market. ### Advancements in Diagnostic Technologies Recent advancements in diagnostic technologies are transforming the Hematuria Treatment Market. Innovations such as non-invasive imaging techniques and enhanced urinalysis methods have improved the accuracy of hematuria diagnosis. For instance, the introduction of advanced biomarkers and molecular diagnostics allows for earlier detection of potential underlying conditions. This technological evolution not only facilitates timely treatment but also enhances patient outcomes, thereby increasing the overall demand for hematuria treatments. As healthcare systems continue to adopt these cutting-edge technologies, the Hematuria Treatment Market is poised for substantial growth, driven by the need for precise and efficient diagnostic solutions. ### Increased Focus on Preventive Healthcare The growing emphasis on preventive healthcare is shaping the Hematuria Treatment Market. As awareness of the importance of early detection and intervention rises, more individuals are seeking medical advice for symptoms such as hematuria. This trend is supported by public health campaigns aimed at educating the population about urinary health. The proactive approach to healthcare encourages regular screenings and check-ups, leading to an uptick in diagnoses of hematuria. Consequently, this heightened awareness drives demand for effective treatment options, thereby contributing to the expansion of the Hematuria Treatment Market. ### Regulatory Support for Innovative Treatments Regulatory bodies are increasingly supporting the development of innovative treatments for hematuria, which is a crucial driver of the Hematuria Treatment Market. Initiatives aimed at expediting the approval process for new therapies and diagnostic tools are fostering a conducive environment for market growth. For instance, regulatory agencies are providing incentives for research and development in the field of urology, encouraging pharmaceutical companies to invest in novel treatment options. This regulatory support not only accelerates the introduction of new products but also enhances competition within the Hematuria Treatment Market, ultimately benefiting patients through improved treatment choices. ## Future Outlook The Hematuria Treatment Market is projected to grow at a 2.7% CAGR from 2025 to 2035, driven by increasing prevalence of urinary disorders and advancements in diagnostic technologies. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection - Expansion of personalized treatment plans based on genetic profiling By 2035, the Hematuria Treatment Market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Gross or Macroscopic Hematuria (Largest) vs. Microscopic Hematuria (Fastest-Growing) The Hematuria Treatment Market exhibits a notable distribution across its segments, with Gross or Macroscopic Hematuria holding the largest market share. This segment is prominently recognized due to its clear presentation of blood in urine, leading to increased patient consultations and subsequent treatment interventions. Microscopic Hematuria, while smaller in share, is rapidly gaining traction as advancements in diagnostic techniques unveil more cases previously unnoticed. Both segments demand attention due to their distinct clinical implications and treatment approaches. Gross or Macroscopic Hematuria: Dominant vs. Microscopic Hematuria: Emerging Gross or Macroscopic Hematuria is characterized by overt blood in the urine, leading to immediate medical evaluation and management. This segment's dominance in the market is propelled by its visibility and the urgency often associated with its presentation. In contrast, Microscopic Hematuria, defined by the presence of blood detected via microscopic examination, is emerging as a significant focus area within the market. Increased awareness and enhanced diagnostic capabilities are driving its growth, with more patients being diagnosed and seeking treatment options. As healthcare providers emphasize early intervention, both segments reveal critical insights into patient management and treatment outcomes. ### By Causes: Kidney Stones (Largest) vs. Urinary Tract Infections (Fastest-Growing) In the Hematuria Treatment Market, the causes of hematuria are diverse, with kidney stones accounting for a significant share due to their prevalence among all age groups. Urinary Tract Infections (UTIs) closely follow, particularly affecting women, creating a notable market for treatments. Other causes like blood cancer and prostate cancer also contribute substantially to market dynamics, but kidney stones remain the most common reason for hematuria cases, influencing treatment demand. While bladder stones and urethritis account for smaller shares, they still play a role, especially in particular demographics and medical histories. The growth of this segment is driven by an increased awareness of hematuria and its underlying causes, along with advancements in diagnostics and treatment options. UTIs, classified as the fastest-growing cause in this market, have seen a surge due to lifestyle changes and increased risk factors, prompting healthcare systems to focus on effective treatments. Simultaneously, kidney stones continue to hold their ground due to their high incidence rates, underscoring a stable demand for existing treatment solutions. As the healthcare landscape evolves, these trends will shape the Hematuria Treatment Market significantly. Kidney Stones (Dominant) vs. Urinary Tract Infections (Emerging) Kidney stones represent the dominant cause in the Hematuria Treatment Market, characterized by a robust need for surgical and non-surgical treatment options. Patients experience intense pain, driving a demand for rapid and effective interventions, including lithotripsy and ureteroscopy. On the other hand, urinary tract infections (UTIs) are emerging as a fast-growing concern due to increased incidence rates, particularly in women, stemming from factors like hormonal changes and increased susceptibility. The treatment landscape for UTIs is rapidly evolving with the introduction of new antibiotics and preventive measures, highlighting the need for healthcare providers to adapt treatment protocols. Both segments thus demonstrate varying market characteristics, with kidney stones retaining dominance while UTIs are capturing increasing attention. ### By Treatment: Drugs (Largest) vs. Therapeutics (Fastest-Growing) The Hematuria Treatment Market is characterized by a robust distribution among its primary segments: Drugs, Therapeutics, and Others. Currently, the Drugs segment holds the largest share, indicating its critical role in managing hematuria. This segment includes various pharmaceuticals that are commonly prescribed for symptomatic relief and underlying causes, making it essential for patient treatment protocols. Following closely, the Therapeutics segment, which is witnessing rapid growth, signifies increasing acceptance and innovation within targeted treatment strategies, aimed at underlying conditions causing hematuria. Drugs: Traditional (Dominant) vs. Therapeutics: Innovative (Emerging) The Drugs segment is considered the dominant force in the Hematuria Treatment Market, encompassing a wide range of traditional pharmacological options such as anti-inflammatory agents, antibiotics, and hemostatic agents. These drugs are integral to immediate symptom management and have a well-established market presence. In contrast, the Therapeutics segment is emerging as a significant player, focusing on advanced treatment modalities such as monoclonal antibodies and targeted therapies. With ongoing research and a trend toward personalized medicine, this segment is expected to revolutionize hematuria management, leveraging innovation to tackle the complexities of underlying diseases. ### By End-Users: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the Hematuria Treatment Market, hospitals dominate the end-user segment, holding the largest share due to their comprehensive treatment capabilities and advanced medical infrastructure. Clinics follow, contributing significantly to the market as they offer convenient and accessible treatment options for patients. Laboratories and research centers play a vital role as well, although their market share is comparatively smaller. The presence of specialized facilities for diagnostics and research aids in developing innovative treatment solutions, enhancing service delivery across the segment. Hospitals (Dominant) vs. Clinics (Emerging) Hospitals represent the dominant force in the Hematuria Treatment Market, equipped with high-level medical technologies and a wide array of specialists that facilitate superior patient care. Their ability to offer immediate treatments and emergency services positions them as the primary choice for many patients suffering from hematuria. Conversely, clinics have emerged as a fast-growing segment, leveraging their accessibility and affordability. They cater to a large patient population seeking quick evaluations and treatments, thus, playing a crucial role in the market's evolution. This growing trend reflects a shift in patient preferences towards outpatient services, driven by an increasing awareness and education around hematuria. ## Regional Market Share Analysis By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The Asia Pacific Hematuria Treatment Market area will be dominant, due to the expansion of healthcare facilities, the prevalence of generic manufacturers, the growth of government initiatives, and the emergence of specialized communities. Further, the major countries studied in the market report are The US, Germany, Canada, France, the United Kingdom, Italy, Spain, Australia, South Korea, and Brazil. **Figure2: HEMATURIA TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)**  Europe Hematuria Treatment Market accounts for the second-largest market share due to the desire for novel therapies, as well as other significant reasons including the enormous research being conducted in the area of treating urinary tract infections, the market participants have begun to expand internationally. Further, the German Hematuria Treatment Market held the largest market share, and the UK Hematuria Treatment Market was the European region's fastest-growing market. The North America Hematuria Treatment Market is predicted to see the highest CAGR between 2023 and 2035. This is because of the early adoption of branded products, favorable healthcare reimbursement regulations, recent FDA permits, the vast number of drugs in development, the emphasis on reducing the overall number of unresolved hematuria cases, and the early treatment of hematuria. Moreover, China’s Hematuria Treatment Market held the largest market share, and the Indian Hematuria Treatment Market was the Asia-Pacific region's fastest-growing market. ## Competitive Benchmarking Leading market players are paying a large sum of money on research and development in order to expand their product lines, which will help the Hematuria Treatment Market, grow even more. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other organizations. To grow and endure in an increasingly competitive and challenging market environment, Hematuria Treatment industry must provide affordable options. One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the Hematuria Treatment industry to benefit clients and increase the market sector. In recent years, the Hematuria Treatment industry has offered some of the most significant advantages to medicine. Major players in the Hematuria Treatment Market, including AstraZeneca Plc. Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Novartis International AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, The Medicines Company and others are making investments in research and development activities in an effort to boost market demand. AstraZeneca plc is a worldwide pharmaceutical and biotechnology business with British and Swedish roots. Its headquarters are in Cambridge, England's Cambridge Biomedical Campus. Its product portfolio covers cancer, cardiovascular, gastrointestinal, infectious, [neurological](https://www.marketresearchfuture.com/reports/neurology-devices-market-9768'), respiratory, and inflammatory illnesses. It has been among the largest pharmaceutical corporations in the world since the merger and has acquired a number of businesses, notably Cambridge Antibody Technology. In 2021, India authorized the use of the Oxford-AstraZeneca vaccine, opening the door for a widespread immunization campaign in the second-most populous nation in the world. It was revealed that the Oxford-AstraZeneca shot would be produced domestically by the Serum Institute of India (SII) under the trade name COVISHIELD. The Bristol-Myers Squibb Company (BMS) is a pharmaceutical company with headquarters in the US. With its headquarters in New York City, one of the largest pharmaceutical companies in the world, BMS routinely makes the Fortune 500 list of the largest American companies. Cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders are among the therapeutic areas where Bristol Myers Squibb produces prescription medications and biologics. Lawrence, New Jersey, Summit, New Jersey, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain are the locations of BMS's main research and development facilities. Additional facilities can be found in Devens and Cambridge in Massachusetts, East Syracuse, New York, Braine-l'Alleud, Belgium, and Tokyo in Japan, India's Bangalore, and Wirral, United Kingdom. In the past, BMS operated an R&D facility in Wallingford, Connecticut. In June BMS announced that it would buy Turning Point Therapeutics Inc. for $4.1 billion in cash ($76 per share, a 122.5% premium to its most recent closing price), expanding its line-up of cancer medications to include repotrectinib. ## Recent News & Developments _**April 2019:**Otsuka Pharmaceutical Co., Ltd. declared that, JYNARQUE (tolvaptan) has been approved by the FDA as the first medication to be used to stop kidney function decline in persons at risk of autosomal dominant polycystic kidney disease increasing quickly._ _**April 2021:**FDA-approved oral tablets of Farxiga (dapagliflozin) to lower the risk of renal function loss, kidney failure, cardiovascular death, and heart failure hospitalization in chronic renal disease patients who are at risk of disease progression._ _**June 2021:**Eisai Co., Ltd. and Bristol-Myers Squibb Company have entered into an exclusive strategic collaboration agreement, in order to jointly develop and market MORAb-202, an antibody drug conjugate (ADC)._ ## Report Scope | MARKET SIZE 2024 | 1.161(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 1.192(USD Billion) | | MARKET SIZE 2035 | 1.556(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.7% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | AstraZeneca (GB), Bristol-Myers Squibb (US), Pfizer (US), Novartis (CH), Roche (CH), Johnson & Johnson (US), Merck & Co. (US), Eli Lilly and Company (US), Sanofi (FR) | | Segments Covered | Type, Causes, Treatment, End-Users, Region | | Key Market Opportunities | Advancements in minimally invasive procedures enhance treatment options in the Hematuria Treatment Market. | | Key Market Dynamics | Rising demand for minimally invasive procedures drives innovation in hematuria treatment options and technologies. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Hematuria Treatment Market?** A: The Hematuria Treatment Market was valued at 1.161 USD Billion in 2024. **Q: What is the projected market size for the Hematuria Treatment Market by 2035?** A: The market is projected to reach 1.556 USD Billion by 2035. **Q: What is the expected CAGR for the Hematuria Treatment Market during the forecast period?** A: The expected CAGR for the Hematuria Treatment Market from 2025 to 2035 is 2.7%. **Q: Which companies are the key players in the Hematuria Treatment Market?** A: Key players include AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Roche, Johnson & Johnson, Merck & Co., Eli Lilly and Company, and Sanofi. **Q: What are the main types of hematuria and their market valuations?** A: Gross or macroscopic hematuria and microscopic hematuria are leading types, valued at 0.623 and 0.516 USD Billion respectively in 2024. **Q: What are the primary causes of hematuria and their market impact?** A: Kidney stones and urinary tract infections are significant causes, with market valuations of 0.4 and 0.35 USD Billion respectively in 2024. **Q: What treatment options are available in the Hematuria Treatment Market?** A: The market for drugs and therapeutics is substantial, with valuations of 0.65 and 0.5 USD Billion respectively in 2024. **Q: Who are the main end-users in the Hematuria Treatment Market?** A: Hospitals and clinics are the primary end-users, valued at 0.623 and 0.309 USD Billion respectively in 2024. **Q: How does the market for idiopathic hematuria compare to other types?** A: Idiopathic hematuria was valued at 0.278 USD Billion in 2024, indicating a notable presence among hematuria types. **Q: What is the market outlook for hematuria treatment in the coming years?** A: The market outlook appears positive, with a projected increase in valuation and steady growth anticipated through 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hematuria-treatment-market-1732*